Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Galera Therapeutics Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
GRTX
Nasdaq
8731
https://www.galeratx.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Galera Therapeutics Inc
Galera Reports Third Quarter 2023 Financial Results and Recent Corporate Updates
- Nov 14th, 2023 12:00 pm
Galera Announces Receipt of Type A Meeting Minutes and Strategic Update
- Oct 31st, 2023 11:00 am
Galera Schedules Type A Meeting with FDA to Discuss Next Steps for Avasopasem
- Sep 18th, 2023 11:00 am
Galera to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
- Sep 5th, 2023 11:00 am
All You Need to Know About Galera Therapeutics, Inc. (GRTX) Rating Upgrade to Buy
- Aug 18th, 2023 4:00 pm
Chevron upgraded, SolarEdge downgraded: Wall Street's top analyst calls
- Aug 16th, 2023 2:00 pm
Galera Reports Second Quarter 2023 Financial Results and Recent Corporate Updates
- Aug 14th, 2023 11:00 am
Biotech Stock Roundup: SAGE, GRTX Plunge on Setback, REGN to Buy DBTX & More News
- Aug 11th, 2023 2:34 pm
Galera shares plunge 85% on FDA rejection; workforce cut by more than half
- Aug 10th, 2023 2:12 pm
Galera shares tank after US FDA declines to approve inflammation disease drug
- Aug 9th, 2023 10:30 pm
Galera Receives Complete Response Letter from U.S. FDA for Avasopasem Manganese
- Aug 9th, 2023 8:31 pm
Despite Galera Therapeutics' Pullback, Insiders Still Gained US$102k
- Jun 28th, 2023 12:11 pm
Galera Presents Additional Chronic Kidney Disease Data from ROMAN Trial at 2023 ASCO Annual Meeting
- Jun 5th, 2023 6:15 pm
Galera Therapeutics, Inc.'s (NASDAQ:GRTX) largest shareholders are retail investors with 45% ownership, institutions own 34%
- May 18th, 2023 12:45 pm
Galera Announces FDA Orphan Drug Designation Granted to Rucosopasem for Pancreatic Cancer
- May 18th, 2023 12:00 pm
Galera Reports First Quarter 2023 Financial Results and Recent Corporate Updates
- May 11th, 2023 11:00 am
Galera Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- May 4th, 2023 8:01 pm
Galera Expands Commercial Leadership Team
- May 1st, 2023 11:00 am
Galera to Present One-Year Reductions in Cisplatin-Related Chronic Kidney Disease Data from ROMAN Trial at 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
- Apr 26th, 2023 2:00 pm
Galera Announces Presentation of Supplemental Analysis of Phase 3 ROMAN Trial at European Congress on Head and Neck Oncology
- Mar 10th, 2023 12:00 pm
Scroll